Inventor · disambiguated record
Jennifer A. Dumont
Also filed as: DUMONT JENNIFER A · DUMONT Jennifer
18 granted patents·13 pending applications·361 citations·filing 1999–2025
95Inventor score
Files withBIOVERATIV THERAPEUTICS INC11DYAX CORP7AVENTIS PHARMA INC6BIOGEN HEMOPHILIA INC2DUMONT JENNIFER A2
Top patents by PatentIndex Score
31 records- 0195US9260520B2Antibodies to FeRn and uses thereofDYAX CORP·Filed 2014·Granted Feb 16, 2016·18 cites·6 claims
- 0294US11266720B2Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 8, 2022·6 cites·64 claims
- 0394US8815246B2Fc receptor binding proteinsTENHOOR CHRISTOPHER·Filed 2012·Granted Aug 26, 2014·18 cites·12 claims
- 0494US8273351B2Fc receptor binding proteinsTENHOOR CHRISTOPHER·Filed 2009·Granted Sep 25, 2012·20 cites·6 claims
- 0593US10881742B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·5 cites·26 claims
- 0693US9050318B2Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereofDUMONT JENNIFER A·Filed 2010·Granted Jun 9, 2015·28 cites·31 claims
- 0791US10023628B2Cell line expressing single chain factor VIII polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jul 17, 2018·6 cites·17 claims
- 0890US9241978B2Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereofBIOGEN HEMOPHILIA INC·Filed 2013·Granted Jan 26, 2016·15 cites·21 claims
- 0989US6413974B16,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purinesAVENTIS PHARMA INC·Filed 1999·Granted Jul 2, 2002·94 cites·27 claims
- 1088US12186375B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Jan 7, 2025·1 cites·19 claims
- 1186US6479487B16, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purinesAVENTIS PHARMA INC·Filed 1999·Granted Nov 12, 2002·78 cites·193 claims
- 1286US2025195620A1Factor viii chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1384US10010622B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofDUMONT JENNIFER A·Filed 2012·Granted Jul 3, 2018·7 cites·22 claims
- 1481US6399633B1Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferationAVENTIS PHARMA INC·Filed 1999·Granted Jun 4, 2002·61 cites·15 claims
- 1577US2022265780A1Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1669US2025121036A1Methods of treating hemophilic arthropathy using chimeric clotting factorsBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1765US2016222110A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 1865US2013045218A1Fc receptor binding proteinsSYNTONIX PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 1964US6861524B2Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agentsAVENTIS PHARMA INC·Filed 2001·Granted Mar 1, 2005·2 cites·10 claims
- 2063US2016194397A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2163US2016222111A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2263US2016222112A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2363US2016222109A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2463US2016222108A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 2561US6642231B26,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purinesAVENTIS PHARMA INC·Filed 2002·Granted Nov 4, 2003·1 cites·21 claims
- 2660US7429595B2Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agentsAVENTIS PHARMA INC·Filed 2003·Granted Sep 30, 2008·1 cites·16 claims
- 2757US12161696B2Methods of treating hemophilic arthropathy using chimeric clotting factorsBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Dec 10, 2024·0 cites·17 claims
- 2855US2019010212A1Cell line expressing single chain factor viii polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2954US2016199455A1Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use ThereofBIOGEN HEMOPHILIA INC·Filed 2015·Application pending·0 cites
- 3052US2025268990A1Methods of inducing immune tolerance to clotting factorsBIOVERATIV THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3151US12257288B2Methods of inducing immune tolerance to clotting factorsBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Mar 25, 2025·0 cites·19 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →